Academic Appointments
- Professor of Neurology and Pediatrics (in the Gertrude H. Sergievsky Center) at CUMC
Dr. Chiriboga is Professor of Neurology and Pediatrics at CUIMC and former Interim Director of the Division of Child Neurology, Departments of Neurology and Pediatrics, Vagelos College of Physicians and Surgeons. She is also former Chief of Pediatric Neurology at Columbia University's affiliate hospital, Harlem Hospital Center.
Dr. Chiriboga was born in Peru and educated in Argentina, where she graduated with Honors from the Faculty of Medicine at the National University of Buenos Aires in 1982. Dr. Chiriboga completed training in pediatrics at St. Luke's-Roosevelt Hospital in 1985. After completing her training in child neurology in 1988 at the Neurological Institute and Babies Hospital of Columbia-Presbyterian Medical Center, Dr. Chiriboga joined the Division of Child Neurology at NewYork-Presbyterian/Columbia University Irving Medical Center. Subsequently, she completed a Neuroepidemiology fellowship at the Gertrude H. Sergievsky Center and received a Master in Public Health from the Mailman School of Public Health, Columbia University. Dr. Chiriboga serves/has served on committees of the NIH, CNS, and ABPN. She is a diplomate of the ABPN in Child Neurology.
Dr. Chiriboga's current research focuses on Spinal Muscular Atrophy (SMA) clinical trials. Past areas of research, including NIH funding, has focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on neuromuscular disorders as well as developmental, neurobehavioral neurology, and migraine, and on the treatment of spasticity.
Dr. Chiriboga's clinical research, including NIH funding, has focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on developmental, neurobehavioral neurology and migraine and on the treatment of spasticity.
Departmental Appointments
- Department of Neurology
Division of Child Neurology - Department of Pediatrics
Board Certifications
- Child Neurology
- Neurology with Special Qualification in Child Neurology
Areas of Expertise
- Pediatric Neurology
- Developmental Disorder
- Headache
- Migraines
- Movement Disorder
Languages Spoken
(in addition to English)
- Spanish
Education and Training
- University of Buenos Aires Medical School
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Residency: St. Lukes Roosevelt Hospital
Locations
CUMC/Harkness Pavilion
180 Fort Washington Avenue
552
New York, NY 10032- For new and current patient appointments, call:
- (212) 342-6867
- Fax:
- (212) 342-6865
Provider Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
- NewYork-Presbyterian Morgan Stanley Children's Hospital
Insurance Programs
Please contact the provider's office directly to verify that your particular insurance is accepted.
- Aetna [EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Signature Administrators, Student Health]
- Cigna [EPO, Great West, HMO, POS, PPO]
- Emblem/GHI [Medicare Managed Care, PPO]
- Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
- Empire Blue Cross/Blue Shield [EPO, Medicare Managed Care, PPO]
- Local 1199 [Local 1199]
- MagnaCare [MagnaCare]
- Multiplan [Multiplan]
- MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
- Oxford Health Plans [Freedom, Liberty]
- UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
This provider sees pediatric patients
This provider accepts new patients
Appointment Phone Number: (212) 342-6867
Links
Lab Locations
CUMC/Harkness Pavilion
180 Fort Washington Avenue
552
New York, NY 10032- Fax:
- (212) 342-6865
NIH Grants
AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY (RAINBOWFISH BN40703) (P&S Industry Clinical Trial)
Feb 21 2019 - Feb 21 2024
CLINICAL RESEARCH SITES FOR THE NETWORK OF EXCELLENCE IN NEUROSCIENCE CLINICAL TRIALS (NEURONEXT SITES) (U24) (Federal Gov)
Jul 1 2018 - Jun 30 2023
AGLOBAL STUDY OF A SINGLE, ONE-TIME DOSE OF AVXS-101 DELIVERED TO INFANTS WITH GENETICALLY DIAGNOSED AND PRE-SYMPTOMATIC SPINAL MUSCULAR ATROPHY WITH MULTIPLE COPIES OF SMN2. (P&S Industry Clinical Trial)
May 7 2018 - May 7 2023
ATWO-PART SEAMLESS ,MULTI-CENTER RANDOMIZED ,PLACEBO-CONTROLLED,DOUBLEBLIND STUDY TO INVESTIGATE THE SAFETY,TOLERABILITY,PHARMACOKINETICS,PHARMCODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCUALR ATROPHY PATIENTS (P&S Industry Clinical Trial)
Apr 2 2018 - Apr 2 2023
PHASE3, OPEN-LABEL, SINGLE-ARM, SINGLE-DOSE GENE REPLACEMENT THERAPY CLINICAL TRIAL FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY TYPE 1 WITH ONE OR TWO SMN2 COPIES DELIVERING AVXS-101 BY INTRAVENOUS INFUSION (STRIVE) (P&S Industry Clinical Trial)
Jul 11 2017 - Jul 11 2022
LT-002 CLINICAL PROTOCOL A LONG TERM FOLLOW UP STUDY OF PATIENTS IN THE CLINCIAL TRIALS FOR SPINAL MUSCULAR ATROPHY RECEIVING AVXS-101 (P&S Industry Clinical Trial)
May 6 2020 - Jun 6 2020
PEDIATRIC MDA CARE CENTER (Private)
Jan 1 2017 - Dec 31 2019
APHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)
Nov 14 2014 - Nov 14 2019
APHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)
Aug 14 2014 - Aug 14 2019
PEDIATRIC NEUROMUSCULAR CLINICAL RESEARCH NETWORK (Private)
Jul 1 2018 - Jun 30 2019
AN OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ISIS 396443 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN ISIS 396443-CS2 OR ISIS 396443-CS10 (P&S Industry Clinical Trial)
Jan 23 2014 - Jan 23 2019
CURE SPINAL MUSCULAR ATROPHY (Private)
Nov 15 2017 - Nov 14 2018
SPINAL MUSCULAR ATROPHY (SMA) BIOMARKERS IN THE IMMEDIATE POSTNATAL PERIOD OF DEVELOPMENT NN101 (Federal Gov)
Sep 30 2011 - Aug 31 2018
COLUMBIA UNIVERSITY MEDICAL CENTER-WEILL CORNELL MEDICAL CENTER NEXT SITE (Federal Gov)
Sep 30 2011 - Aug 31 2018
SMA FOUNDATION CENTER GRANT (Private)
Jul 1 2015 - Jun 30 2018
COLUMBIA UNIVERSITY MEDICAL CENTER-WEILL CORNELL MEDICAL CENTER NEXT SITE (Federal Gov)
Sep 30 2011 - Jun 30 2018
ASTUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF ISIS 396443 DELIVERED INTRATHECALLY TO PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY. (P&S Industry Clinical Trial)
Jun 4 2013 - Jun 4 2018
ANOPEN-LABEL, DOSE ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY AND DOSE-RANGE FINCING OF MULTIPLE DOSES OF ISIS 396443 DELIVERD INTRATHECALLY TO PATIENTS WITH SMA. (P&S Industry Clinical Trial)
Mar 14 2013 - Mar 14 2018
ANOPENLABEL, ESCALATING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND DOSE RANGE FINDING OF MULTIPLE INTRATHECAL DOSES OF ISIS 396443 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY (P&S Industry Clinical Trial)
Oct 25 2012 - Oct 25 2017
ISIS (P&S Industry Clinical Trial)
Dec 2 2011 - Dec 2 2016
PEDIATRIC NEUROMUSCULAR CLINICAL RESEARCH NETWORK FOR SMA (Private)
Jul 1 2012 - Jun 30 2015
COLUMBIA SMA PROJECT: 4-AP AS A POTENTIAL SMA THERAPEUTIC AGENT AND BIOLOGICAL MECHANISMS OF ACTION (Federal Gov)
Sep 1 2011 - Aug 31 2014
GIBLIN RESEARCH FUND FOR PEDIATRIC NEUROLOGY (Private)
Jul 1 1994 - Dec 31 2013
GIBLIN RESEARCH FUND FOR PEDIATRIC NEUROLOGY (Private)
Jul 1 1994 - Dec 31 2013
PEDIATRIC NEUROMUSCULAR CLINICAL RESEARCH (Private)
Jul 1 2004 - Jun 30 2012
HARLEM HOSPITAL AFFILIATION CONTRACT - GENERAL (NY Local Gov)
Jul 1 2005 - Jun 30 2008
